bioAffinity Expands Government Reach with AvMEDICAL Distribution Deal for CyPath Lung — bioAffinity Technologies, Inc.

Event summary

bioAffinity Technologies has signed a nationwide distribution agreement with AvMEDICAL to expand CyPath Lung's reach in federal healthcare systems.
AvMEDICAL, a Service-Disabled Veteran-Owned Small Business (SDVOSB), will leverage its government contracting expertise to promote CyPath Lung to federal customers, including the VA.
The deal aims to address the high incidence of lung cancer among veterans, with nearly 8,000 diagnoses annually according to the VA.
CyPath Lung demonstrated 92% sensitivity and 87% specificity in detecting lung cancer in high-risk patients with small indeterminate lung nodules.

The big picture

This partnership underscores the strategic importance of government healthcare systems as a growth channel for diagnostic technologies. With lung cancer being a high priority for the VA, the deal positions bioAffinity to capitalize on the unmet need for early detection tools among veterans. The collaboration also highlights the advantage of working with an SDVOSB like AvMEDICAL, which simplifies procurement processes for federal agencies.

What we're watching

Government Adoption: How quickly federal healthcare systems, particularly the VA, will integrate CyPath Lung into their diagnostic protocols.
Commercial Momentum: Whether bioAffinity can sustain its commercial momentum through this new distribution channel.
Regulatory Compliance: The pace at which regulatory developments may impact the use of laboratory-developed tests like CyPath Lung.